Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial P...
08 Juillet 2020 - 6:25PM
Business Wire
Therapeutics Acquisition Corp. (the “Company”) announced today
that it priced its initial public offering of 11,800,000 shares of
Class A common stock at $10.00 per share. The shares will be listed
on the Nasdaq Capital Market and trade under the ticker symbol
“TXAC” beginning July 8, 2020. The Company expects the offering to
be consummated on July 10, 2020.
The Company, sponsored by RA Capital Management, L.P., is led by
Chairman and CEO Peter Kolchinsky PhD and CFO Matthew Hammond PhD.
The Company is a blank check company formed for the purpose of
effecting a business combination with one or more businesses in the
healthcare industry.
Jefferies LLC is serving as the sole book runner for the
offering. The Company has granted the underwriter a 45-day option
to purchase up to an additional 1,770,000 shares of Class A common
stock at the initial public offering price to cover
over-allotments, if any.
The offering is being made only by means of a prospectus. When
available, copies of the prospectus may be obtained from: Jefferies
LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10002, by telephone: 877-821-7388
or by email: Prospectus_Department@Jefferies.com.
Registration statements relating to these securities became
effective on July 7, 2020. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or jurisdiction.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute
“forward-looking statements,” including with respect to the initial
public offering and the anticipated use of the net proceeds. No
assurance can be given that the offering discussed above will be
completed on the terms described, or at all, or that the net
proceeds of the offering will be used as indicated. Forward-looking
statements are subject to numerous conditions, many of which are
beyond the control of the Company, including those set forth in the
Risk Factors section of the Company’s registration statement and
preliminary prospectus for the offering filed with the Securities
and Exchange Commission (“SEC”). Copies are available on the SEC’s
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200708005746/en/
RA Capital Management, L.P. Matthew Hammond 617-778-2540
Therapeutics Acquisition (NASDAQ:TXAC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Therapeutics Acquisition (NASDAQ:TXAC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024